Is valproic acid (Depakote) safe during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Depakote (Valproic Acid) is NOT Safe During Pregnancy

Valproic acid is contraindicated during pregnancy and should not be used in women of childbearing potential unless no other effective alternatives exist. The drug carries the highest teratogenic risk among antiseizure medications, causing major congenital malformations, neurodevelopmental impairment, and long-term cognitive deficits in exposed children 1, 2.

Critical Risks to the Fetus

Major Congenital Malformations

Valproic acid exposure during pregnancy significantly increases the risk of multiple severe birth defects compared to other antiseizure medications:

  • Neural tube defects: 6.5-fold increased risk (including spina bifida) 3
  • Congenital heart defects: 2.5-fold increased risk 3
  • Cleft lip/palate: 4.3-fold increased risk 3
  • Genitourinary anomalies: 3.3-fold increased risk 3
  • Musculoskeletal anomalies: 2.9-fold increased risk 3

These defects can begin forming in the first month of pregnancy, even before you know you're pregnant 2. The overall malformation rate ranges from 8-15%, which is substantially higher than other antiseizure medications 4.

Neurodevelopmental Impairment

Beyond physical malformations, valproic acid causes dose-dependent cognitive impairment in exposed children 1:

  • Lower IQ scores
  • Increased risk of autism spectrum disorder
  • Increased risk of attention deficit/hyperactivity disorder (ADHD)
  • Potential hearing loss or decreased hearing 2

Current Guidelines and Regulatory Position

Current 2026 guidelines explicitly state that valproic acid is "not recommended" for use during pregnancy 1. The European Medicines Agency has issued safety communications advising against valproate use in women of childbearing potential 1.

Absolute Contraindications

  • Pregnant women must NOT take Depakote to prevent migraine headaches 2
  • Women who cannot reliably exclude pregnancy should receive alternative medications

When Valproate Might Be Considered (Rare Exceptions)

Valproate should only be used if:

  1. Alternative antiseizure medications are ineffective or intolerable
  2. The patient has specific epilepsy syndromes (e.g., juvenile myoclonic epilepsy, certain generalized epilepsies) where valproate has superior documented efficacy 1, 5
  3. If absolutely necessary, daily dose should not exceed 650 mg and must be divided into 3-4 doses to minimize peak concentrations 1

Recommended Alternatives

First-line antiseizure medications for women of childbearing potential are lamotrigine and levetiracetam 1. These have significantly lower teratogenic risk profiles:

  • Lamotrigine: Recommended for both focal and generalized seizures
  • Levetiracetam: Recommended for both focal and generalized seizures
  • Oxcarbazepine: Alternative for focal epilepsy when lamotrigine/levetiracetam are unsuitable

Risk of Switching Medications

Switching from valproic acid to alternatives carries approximately 20% risk of seizure recurrence or worsening 4. However, this risk must be weighed against the severe and permanent harm to the fetus. Factors increasing seizure recurrence risk include:

  • Shorter duration of seizure remission before switch
  • Higher valproate doses
  • Multiple seizure types
  • Catamenial seizure patterns

Essential Clinical Actions

For All Women of Childbearing Potential on Valproate

  1. Immediate counseling required: Discuss teratogenic risks and alternative treatments at first prescription and at least annually 1
  2. Mandatory effective contraception: If valproate must be continued, reliable birth control is essential 2
  3. Written information: Provide documentation about risks of major congenital malformations and intellectual disability 1
  4. Pregnancy Prevention Program adherence: Required for all women who cannot exclude pregnancy 6

If Pregnancy Occurs on Valproate

  1. Do NOT abruptly discontinue: Sudden withdrawal can cause status epilepticus 2
  2. Immediate consultation: Contact healthcare provider to discuss continuing versus switching
  3. High-dose folic acid: 4-8 mg daily (though this does NOT eliminate teratogenic risk, it may reduce neural tube defects) 1
  4. Registry enrollment: Consider enrolling in the North American Antiepileptic Drug Pregnancy Registry (1-888-233-2334) 2

Common Pitfalls to Avoid

  • Never assume "low dose is safe": While risk is dose-dependent, even lower doses carry significant teratogenic risk 3
  • Don't delay switching: Optimize medication before conception whenever possible 1
  • Don't prioritize seizure control over fetal safety without informed consent: This requires detailed shared decision-making, particularly as evidence suggests treatment choices sometimes inappropriately prioritize fetal safety at expense of maternal seizure control in certain populations 1
  • Don't forget that defects occur early: Critical period is days 21-28 of gestation, often before pregnancy recognition 1

Bottom Line

Valproic acid should be avoided in all women who could become pregnant unless absolutely no other effective option exists. The evidence is unequivocal: valproate causes the highest rate of birth defects and neurodevelopmental impairment among antiseizure medications. Lamotrigine and levetiracetam are safer first-line alternatives. If valproate is unavoidable for specific refractory epilepsy syndromes, use the lowest effective dose (≤650 mg/day in divided doses), ensure reliable contraception, and provide comprehensive informed consent about the substantial risks to any potential pregnancy 1, 2, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.